Mitoxantrone

• 产品号: DB01204
• CAS号: 65271-80-9
• 分子式: C22H28N4O6
• 分子量: 444.48092

产品别名

• 标题: Mitoxantrone
• IUPAC标准名: 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione
• IUPAC传统名: mitoxantrone
• 商标名: Mitox; Novantrone; Novantron
• 别名: DHAQ; Mitozantrone; Dihydroxyanthraquinone; DHAD; DHAQ HCl; Mitoxantrone hydrochloride; Mitoxanthrone; Mitoxantron; Mitoxantrone 2HCl; Mitoxantrone dihydrochloride; Mitoxantrone HCl; Mitoxantronum [INN-Latin]; mitoxantrone; Mitoxantrona [INN-Spanish]; Mitozantrone hydrochloride

产品登记号

• CAS号: 65271-80-9
• PubChem SID: 46504608
• PubChem CID: 4212

产品性质

• 疏水性(logP): -3.1

产品详细信息

详细说明 (English)

• Drug Groups: approved; investigational
• Description: An anthracenedione-derived antineoplastic agent. [PubChem]
• Indication: For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
• Pharmacology: Mitoxantrone has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.
• Toxicity: Severe leukopenia with infection.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic
• Absorption: Poorly absorbed following oral administration
• Half Life: 75 hours
• Protein Binding: 78%
• Distribution: * 1000 L/m2
• Clearance: * 21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2]; * 28.3 L/hr/m2 [Non-elderly patients with nasopharyngeal carcinoma receiving IV administration of 15-90 mg/m2]; * 16.2 L/hr/m2 [Non-elderly patients with malignant lymphoma receiving IV administration of 15-90 mg/m2]
• References: Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther. 2006 Apr;28(4):461-74. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

参考文献

• Fox EJ: Management of worsening multiple sclerosis with mitoxantrone: a review. Clin Ther. 2006 Apr;28(4):461-74. Pubmed